Santosh Pasha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3006522/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Self assembly and hydrogelation of N-terminal modified tetrapeptide for sustained release and synergistic action of antibacterial drugs against methicillin resistant S. aureus. Bioorganic Chemistry, 2020, 102, 104052.	4.1	10
2	Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors. Bioorganic Chemistry, 2018, 78, 158-169.	4.1	61
3	Novel Miniature Membrane Active Lipopeptidomimetics against Planktonic and Biofilm Embedded Methicillin-Resistant Staphylococcus aureus. Scientific Reports, 2018, 8, 1021.	3.3	22
4	Design and synthesis of cell selective α/β-diastereomeric peptidomimetic with potent in vivo antibacterial activity against methicillin resistant S. Aureus. Bioorganic Chemistry, 2018, 76, 538-547.	4.1	16
5	Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors. European Journal of Medicinal Chemistry, 2017, 126, 853-869.	5.5	81
6	Effects of a novel ACE inhibitor, 3-(3-thienyl)-L-alanyl-ornithyl-proline, on endothelial vasodilation and hepatotoxicity in L-NAME-induced hypertensive rats. Drug Design, Development and Therapy, 2016, 10, 1533.	4.3	13
7	<scp>NPYF</scp> a, A Chimeric Peptide of Metâ€Enkephalin, and <scp>NPFF</scp> Induces Toleranceâ€Free Analgesia. Chemical Biology and Drug Design, 2016, 87, 885-894.	3.2	4
8	Self assembly and hydrogelation of spermine functionalized aromatic peptidomimetics against planktonic and sessile methicillin resistant S.Âaureus. RSC Advances, 2016, 6, 112656-112666.	3.6	9
9	N-terminal aromatic tag induced self assembly of tryptophan–arginine rich ultra short sequences and their potent antibacterial activity. RSC Advances, 2015, 5, 68610-68620.	3.6	19
10	N-Terminally Modified Linear and Branched Spermine Backbone Dipeptidomimetics against Planktonic and Sessile Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2014, 58, 5435-5447.	3.2	19
11	Antimicrobial activity and mode of action of novel, N-terminal tagged tetra-peptidomimetics. MedChemComm, 2013, 4, 874.	3.4	7
12	Sulfur-Containing Angiotensin-Converting Enzyme Inhibitor 3-Thienylalanine-Ornithyl-Proline Activates Endothelial Function and Expression of Genes Involved in Renin–Angiotensin System. Journal of Cardiovascular Pharmacology, 2013, 61, 311-317.	1.9	4
13	Comparative mode of action of novel hybrid peptide <scp>CS</scp> â€l a and its rearranged amphipathic analogue <scp>CS</scp> â€2a. FEBS Journal, 2012, 279, 3776-3790.	4.7	8
14	Synthesis, antibacterial activity and mode of action of novel linoleic acid–dipeptide–spermidine conjugates. Organic and Biomolecular Chemistry, 2012, 10, 8326.	2.8	23
15	Comparative modeling of human kappa opioid receptor and docking analysis with the peptide YFa. Journal of Molecular Graphics and Modelling, 2012, 33, 44-51.	2.4	3
16	Intracellular cAMP assay and Eu-GTP-γS binding studies of chimeric opioid peptide YFa. European Journal of Pharmacology, 2011, 650, 28-33.	3.5	5
17	YFa and analogs: Investigation of opioid receptors in smooth muscle contraction. World Journal of Gastroenterology, 2011, 17, 4523.	3.3	3
18	Rationally designed chimeric peptide of met-enkephalin and FMRFa-[D-Ala2, p-Cl-Phe4]YFa induce multiple opioid receptors mediated antinociception and up-regulate their expression. European Journal of Pharmacology, 2010, 638, 54-60.	3.5	2

Santosh Pasha

#	Article	IF	CITATIONS
19	Effect of chronic intraâ€peritoneally administered chimeric peptide of metâ€enkephalin and FMRFaâ€{ <scp>d</scp> â€Ala ²]YFaâ€on antinociception and opioid receptor regulation. European Journal of Pain, 2010, 14, 295.e1-9.	2.8	3
20	Interaction studies of novel cell selective antimicrobial peptides with model membranes and E. coli ATCC 11775. Biochimica Et Biophysica Acta - Biomembranes, 2010, 1798, 1864-1875.	2.6	80
21	Various drug delivery approaches to the central nervous system. Expert Opinion on Drug Delivery, 2010, 7, 113-135.	5.0	31
22	Endogenous peptide: Met-enkephalin-Arg-Phe, differently regulate expression of opioid receptors on chronic treatment. Neuropeptides, 2009, 43, 355-362.	2.2	9
23	Nanoparticles of cationic chimeric peptide and sodium polyacrylate exhibit striking antinociception activity at lower dose. Journal of Controlled Release, 2009, 134, 47-54.	9.9	8
24	Effect of varying chain length between P1 and P1′ position of tripeptidomimics on activity of angiotensin-converting enzyme inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4364-4366.	2.2	28
25	Effect of 3-Thienylalanine-Ornithine-Proline, New Sulfur-containing Angiotensin-converting Enzyme Inhibitor on Blood Pressure and Oxidative Stress in Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2009, 53, 145-150.	1.9	12
26	YFa, a chimeric opioid peptide, induces kappaâ€specific antinociception with no tolerance development during 6 days of chronic treatment. Journal of Neuroscience Research, 2008, 86, 1599-1607.	2.9	17
27	Lack of tolerance and morphine-induced cross-tolerance to the analgesia of chimeric peptide of Met-enkephalin and FMRFa. Peptides, 2008, 29, 2266-2275.	2.4	9
28	Synthesis, conformational and pharmacological studies of glycosylated chimeric peptides of Met-enkephalin and FMRFa. Brain Research Bulletin, 2006, 68, 329-334.	3.0	11
29	Chimeric peptide of met-enkephalin and FMRFa: Effect of chlorination on conformation and analgesia. Neuroscience Letters, 2006, 403, 131-135.	2.1	11
30	Structure–activity relationship study between Ornithyl-Proline and Lysyl-Proline based tripeptidomimics as angiotensin-converting enzyme inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2117-2121.	2.2	15
31	Novel peptidomimics as angiotensin-Converting enzyme inhibitors: A combinatorial approach. Bioorganic and Medicinal Chemistry, 2002, 10, 3685-3691.	3.0	17
32	Effects of intracerebroventricularly administered chimeric peptide of metenkephalin and FMRFa—[D-Ala2]YFa—on antinociception and its modulation in mice. Brain Research Bulletin, 2001, 55, 51-57.	3.0	10
33	Chimeric peptide of Met-enkephalin and FMRFa induces antinociception and attenuates development of tolerance to morphine antinociception. Peptides, 1999, 20, 471-478.	2.4	26